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Increased risk of cardiac arrest with 
commonly used non-steroidal anti-
inflammatory drugs
The non-steroidal anti-inflammatory drugs (NSAIDs) diclofenac and 
ibuprofen are associated with a significantly inreased risk of cardiac 
arrest, according to a Danish study published in the European Heart 
Journal: Cardiovascular Pharmacotherapy.
Researchers used the Danish Cardiac Arrest Registry to identify 
all individuals who had a cardiac arrest out of hospital between 2001 
and 2010. Of the 28 947 people identified, 3 376 had been treated with 
an NSAID up to 30 days before their cardiac arrest. Each case was 
matched with four controls from the Danish Patient Registry.
Ibuprofen and diclofenac were the most commonly used NSAIDs, 
representing 51% and 22% of total NSAID use, respectively. The 
study found that use of any NSAID was associated with a 31% 
increased risk of cardiac arrest. Diclofenac was associated with a 50% 
increased risk of cardiac arrest (odds ratio (OR) 1.50, 95% confidence 
interval (CI) 1.23 - 1.82), and ibuprofen was associated with a 31% 
increased risk (OR 1.31, 95% CI 1.14 - 1.51).
The study found no significant association between cardiac arrest 
and the COX-2 selective inhibitors celecoxib and rofecoxib, or with 
the unselective NSAID naproxen. However, these drugs are rarely 
used in Denmark so relatively few events occurred, leading to low 
statistical power.
The authors say that the study is a stark reminder that NSAIDs 
are not harmless and should not be used without advice from a 
healthcare professional.
Sondergaard  K,  Weeke  P,  Wissenberg  M,  et al. Non-steroidal anti-inflammatory drug use is associated 
with increased risk of out-of-hospital cardiac arrest: A nationwide case-time-control study.  Eur Heart J 
Cardiovasc Pharmacother 2017;3(2):100-107. http://dx.doi.org/10.1093/ehjcvp/pvw041
Measure blood pressure over  
30 minutes to reduce treatment
Automated blood pressure monitoring over 30 minutes reduces 
not only the number of patients diagnosed with hypertension 
but also the number diagnosed as needing a change to existing 
hypertension treatment, according to a primary care study carried 
out on 201 consecutive patients (mean age 68.6 years) visiting a single 
primary healthcare centre in The Netherlands over 6 months in 2016.
Researchers measured patients’ blood pressure every 5 minutes 
over 30 minutes using an automated blood pressure monitor. They 
compared the average readings with previous routine blood pressure 
measurements. The results, reported in the Annals of Family Medicine, 
showed that mean systolic blood pressure when measured over 
30 minutes was 22.8 mmHg (95% confidence interval (CI) 19.8 - 26.1) 
lower than the mean found on standard measurement. The mean 
diastolic blood pressure on automated monitoring for 30 minutes 
was 11.6 mmHg (95% CI 10.2 - 13.1) lower. This backs up previous 
research showing that up to one-third of patients have white-coat 
hypertension, which falls to normal levels in other settings.
Based on standard blood pressure measurement, GPs at the 
health centre said that they would have started or intensified 
hypertension treatment in 79.1% (73.6 - 84.6%) of patients in the 
study. With results from automated blood pressure monitoring for 
30 minutes, this figure fell to only 24.9% (18.9 - 30.9%).
Bos MJ, Buis S. 2017. Thirty-minute office blood pressure monitoring in primary care. Ann Fam 
Med 2017;15(2):120-123. http://dx.doi.org/10.1370/afm.2041
Insomnia linked with increased risk  
of stroke and myocardial infarction
Insomnia is associated with an increased risk of future myocardial 
infarction (MI) and stroke, according to a meta-analysis of pro-
spective cohort studies published in the European Journal of 
Preventive Cardiology. The study included 15 prospective studies 
following up 160 876 adults aged >18 years for at least 2 years. The 
median follow-up ranged from 3 to nearly 30 years, during which 
time 11 702  adverse events were recorded.
The results showed that non-restorative sleep and difficulty falling 
asleep and staying asleep were associated with an increased risk of 
future cardiovascular events, including incidences of or death due to 
acute MI, coronary heart disease, heart failure, stroke or combined 
events. Early-morning waking was not associated with an increased 
risk of adverse events.
The underlying mechanism for the links is not understood, but 
the authors point out that sleep disorders are common in the general 
population and that sleep health should be included in a clinical risk 
assessment.
He Q, Zhang P, Li G, Dai H, Shi J. The association between insomnia symptoms and risk of cardio-cerebral 
vascular events: A meta-analysis of prospective cohort studies. Eur J Prev Cardiol 2017 (epub 30 March 
2017). http://dx.doi.org/10.1177/2047487317702043
Vitamin E, selenium do not prevent 
dementia
Taking vitamin E or selenium supplements does not prevent dementia 
in asymptomatic older men, according to a study published in JAMA 
Neurology.
The Prevention of Alzheimer’s Disease by Vitamin E and Selenium 
(PREADViSE) trial was piggybacked onto a larger randomised 
controlled trial looking at the antioxidant effects of selenium and 
vitamin E on the incidence of prostate cancer. The parent trial started 
in 2002, but was stopped in 2009 after a planned futility analysis 
showed no effects on prostate cancer incidence.
The trial recruited 7 540 men with a mean age of 67.5 years who 
were randomly assigned to receive vitamin E, selenium, vitamin E 
and selenium, or placebo. They were given antioxidant supplements 
for an average of 5.4 years and assessed using a cognitive screen. 
When the parent trial ended, a subset of 3 786 men received no 
additional supplements but continued to be observed for up to 
6 more years.
Although oxidative stress has been implicated in Alzheimer’s 
disease, the role of antioxidant supplements in disease prevention 
is not known. This study shows that using vitamin E and selenium 
supplements do not prevent dementia and should not be used for 
prevention.
Kryscio RJ, Abner EL, Caban-Holt A, et al. Association of antioxidant supplement use and dementia in the 
prevention of Alzheimer’s disease by vitamin E and selenium trial (PREADVISE). JAMA Neurol 2017 (epub 
20 March 2017). http://dx.doi.org/10.1001/jamaneurol.2016.5778
Increased risk of all-cause mortality  
if overweight at any time
Those who are overweight or obese at any stage of their lives have a 
greater risk of death from cardiovascular disease, cancer and other 
causes than those who maintain a normal weight. This is the result 
of an analysis of three large cohort studies published in the Annals 
of Internal Medicine. The data were from the Nurses’ Health Study I 
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and II and the Health Professionals Follow-up Study, which included 
225 072 men and women. Each participant had a maximum body 
mass index (BMI) recorded over 16 years of weight history and a 
single baseline BMI recorded after this period. Subjects were then 
followed up for a mean of 12.3 years, during which time there were 
32 571 deaths.
As found in previous research, the overweight category as defined 
by a single baseline BMI was not associated with an increased 
risk of death. However, when the maximum BMI was used, it was 
clearly associated with a significant but modest increase in risk. For 
those who had been obese at any stage, the risk was even higher. 
There were no exclusions based on a history of smoking or illness, 
and the pattern of excess risk with a maximum BMI above normal 
weight held for all ages, regardless of sex. The highest risk for death 
was among participants who had substantial decreases in weight, 
probably caused by illness.
Researchers say that looking at a person’s weight history reverses 
the paradoxical association between overweight and reduced mortal-
ity seen in some studies.
Yu E, Ley SH, Manson JE, et al. 2017. Weight history and all-cause and cause-specific mortality in three 
prospective cohort studies. Ann Intern Med 2017;(epub 4 April 2017).  http://dx.doi.org/10.7326/M16-
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